Steven M. Greenberg, MD, PhD, FAHA, Chair; Wendy C. Ziai, MD, MPH, FAHA, Vice Chair;
Charlotte Cordonnier, MD, PhD; Dar Dowlatshahi, MD, PhD, FAHA; Brandon Francis, MD …

Poststroke cognitive impairment and dementia (PSCID) is a major source of morbidity and
mortality after stroke worldwide. PSCID occurs as a consequence of ischemic stroke …

Cerebral small vessel disease (SVD) is common during ageing and can present as stroke,
cognitive decline, neurobehavioural symptoms, or functional impairment. SVD frequently …

Cerebral small vessel disease (SVD) causes lacunar stroke and intracerebral hemorrhage,
and is the most common pathology underlying vascular cognitive impairment. Increasingly …

Cerebral amyloid angiopathy (CAA) is an important cerebral small vessel disease
associated with brain haemorrhage and cognitive change. The commonest form, sporadic …

Objectives Cerebral microbleeds are associated with the risks of ischemic stroke and
intracranial hemorrhage, causing clinical dilemmas for antithrombotic treatment decisions …

Cerebrovascular disease is a major cause of cognitive decline and dementia. This is
referred to as vascular cognitive impairment (VCI). Diagnosing VCI is important, among …

Balancing the risks of recurrent ischemia and antithrombotic-associated bleeding,
particularly intracranial hemorrhage (ICH), is a key challenge in the secondary prevention of …

Background Intracerebral haemorrhage (ICH) has high mortality in the acute phase and
poor functional outcome in the majority of survivors. ICH recurrence is a major determinant …

Antithrombotic therapy is a key element of secondary prevention in patients who have had
an ischaemic stroke or transient ischaemic attack. However, its use in clinical practice is not …